Acute Localized Exanthematous Pustulosis Due to Alendronate

Bautista-Villanueva, S; Galleani, Celine; Barranco, Ruth; Bellón, Teresa; Blanco, Maria Diez; García-Moguel, Ismael

doi:10.18176/jiaci.0709

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hormonal therapies, including letrozole and mifepristone have been implicated in AGEP [ 92 , 138 , 139 ]. Other drugs such as alendronate, benzocaine, cannabidiol, dupilumab, finasteride, isotretinoin, methimazole, mianserin, midodrine, pantoprazole, pseudoephedrine/fexofenadine, and varenicline have also been reported [ 126 , 140 – 150 ].…”

Section: Pathogenesismentioning

confidence: 99%

Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management

et al. 2023

View full text Add to dashboard Cite

Acute generalized exanthematous pustulosis (AGEP) is a rare, acute, severe cutaneous adverse reaction mainly attributed to drugs, although other triggers, including infections, vaccinations, ingestion of various substances, and spider bites, have also been described. AGEP is characterized by the development of edema and erythema followed by the eruption of multiple punctate, non-follicular, sterile pustules and subsequent desquamation. AGEP typically has a rapid onset and prompt resolution within a few weeks. The differential diagnoses for AGEP are broad and include infectious, inflammatory, and drug-induced etiologies. Diagnosis of AGEP depends on both clinical and histologic criteria, as cases of overlap with other disease processes have been reported. Management includes removal of the offending drug or treatment of the underlying cause, if necessary, and supportive care, as AGEP is a self-limited disease. This review aims to provide an overview and update on the epidemiology, pathogenesis, reported precipitating factors, differentials, diagnosis, and management of AGEP.

show abstract

Section: Pathogenesismentioning

confidence: 99%

Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management

et al. 2023

View full text Add to dashboard Cite

show abstract

Alendronic acid

2021

Reactions Weekly

View full text Add to dashboard Cite

Cerium-Doped, Alendronate-Loaded, Metal–Organic Framework Nanodrug for Delayed Osteoporosis Progress

Yao,

Zhang,

Weng

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Osteoporosis (OP) is a global disease featured by decreased osteogenesis and overactivation of osteoclast generation with chronic inflammation, which has no satisfactory treatment currently. Accordingly, normalizing the inflammatory microenvironments by introducing osteogenic and anti-inflammatory agents is emerging as a promising approach for OP treatment. Herein, zincbased zeolite imidazolium skeleton (ZIF-8) nanoparticles (NPs) are doped with cerium ions, loaded with alendronate sodium (Aln), and coated with poly(sodium 4-styrenesulfonate) (PSS) (Aln/PSS@ZIF-8:Ce) for OP treatment. The NPs can be uniformly dispersed and remain stable at pH = 7.4 and gradually release Aln and Ce ions at pH = 6.8, thus potentially providing antioxidative activity in OP microenvironments. The in vitro study indicates that the NPs can not only promote osteogenic differentiation and biomineralization, but also inhibit osteoclast formation and bone resorption by inhibiting reactive oxygen species production, mitogen-activated protein kinase, and nuclear factor κ-B signaling pathways. After intravenous injection into OP mice, the Aln/PSS@ZIF-8:Ce NPs due to their nanoscale properties can significantly reduce bone loss and delay OP progression. Additionally, the NPs exhibit good cytocompatibility in vitro and good histocompatibility in vivo with no adverse reaction. This study demonstrates the efficacy of Aln/PSS@ZIF-8:Ce NPs to normalize OP microenvironments and delay OP progression, and the NPs also hold promise for application in other inflammation-related diseases.

show abstract

Acute Localized Exanthematous Pustulosis Due to Alendronate

Cited by 5 publications

References 0 publications

Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management

Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management

Alendronic acid

Cerium-Doped, Alendronate-Loaded, Metal–Organic Framework Nanodrug for Delayed Osteoporosis Progress

Contact Info

Product

Resources

About